Ovarian aromatase activity in polycystic ovarian syndrome

Cover Page


Cite item

Full Text

Abstract

41 women with polycystic ovary syndrome (PCOS) and 15 healthy women of reproductive age were examined to evaluate ovarian aromatase activity. Aromatase activity was determined by the decrease of estradiol level after peroral intake of aromatase inhibitor letrosol. To examine aromatase activity of antral follicle (∆E2) was divided on the blood level of antimullerian hormone (AMH), which is corresponded to the number of antral follicles. Significant variations of aromatase activity of antral follicles in patients with PCOS were determined: in 34.1 % of women it was within physiological ranges, in 48.8 % of women it was decreased and in 17.1 % of women it was increased. Aromatase activity of antral follicles in patients with PCOS correlated with blood levels of estradiol (r = 0.67), estron (r = 0.27), free testosterone(r = 0.43), androstendion (r = 0.34) and body mass index (r = 0.30). Aromatase activity had reverse correlation with number of antral follicles. Athors suggest that the sensitivity of the ovaries to gonadotropinic stimulation is decreased in patients with PCOS and low aromatase activity.

About the authors

Igor Pavlovich Nikolayenkov

D. O. Ott Research Institute of Obstetrics and Gynecology, RAMS

Email: Nikolaenkov_igor@mail.ru
PhD student

Vladimir Vsevolodovich Potin

D. O. Ott Research Institute of Obstetrics and Gynecology, RAMS

Email: iagmail@ott.ru
PhD, Honoured figure, professor, Head of Gynecological Endocrinilogy Department

Marina Anatolyevna Tarasova

D. O. Ott Research Institute of Obstetrics and Gynecology, RAMS

Email: tarasova@ott.ru
MD, PhD, specialist, professor

Natalya Nikolayevna Tkachenko

D. O. Ott Research Institute of Obstetrics and Gynecology, RAMS

Head of hormone laboratory of the Reproductive Endocrinology Department, Senior Researcher, Candidate of biological science

Maria Igorevna Yarmolinskaya

D. O. Ott Research Institute of Obstetrics and Gynecology, RAMS

Email: m.yarmolinskaya@gmail.com
MD, PhD, Leading Scientific Researcher of the department of reproductive endocrinology

Yekaterina Mikhaylovna Timofeyeva

D. O. Ott Research Institute of Obstetrics and Gynecology, RAMS

Email: katisun@rambler.ru
Doctor of Clinical Laboratory Diagnostics

Yanina Andreyevna Samoylovich

D. O. Ott Research Institute of Obstetrics and Gynecology, RAMS

Email: yanasam@yandex.ru
PhD student

References

  1. Беляков Н. А., Чубриева С. Ю., Глухов Н. В. Инсулинорезистентность и синдром поликистозных яичников. Часть II. Патогенез, роль гиперинсулинемии и гиперандрогенемии, генетическая взаимосвязь. Эфферентная терапия. 2002; 8 (3): 16-29.
  2. Дедов И. И., Мельниченко Г. А. ред. Синдром поликистозных яичников: руководство для врачей. М.: МИА; 2007.
  3. Денисова В. М. Эффективность агониста гонадотропин-рилизинг гормона в терапии эндометриоза. Журнал акушерства и женских болезней. 2013; 5: 29-34.
  4. Савина В. А. Овариальная ароматаза р450 при нормогонадотропной недостаточности яичников. Журнал акушерства и женских болезней. 2012; 1: 84-9.
  5. Савина В. А., Кветной И. М., Клещев М. А., Потин В. В., Рулев В. В., Тарасова М. А., Ткаченко Н. Н., Ярмолинская М. И. Овариальная ароматаза р450 при синдроме поликистозных яичников. Медицинский академический журнал. 2012; 12 (1): 66-72.
  6. Савина В. А., Швед Н. Ю., Потин В. В., Тарасова М. А., Ярмолинская М. И., Иващенко Т. Э., Баранов В. С. Аллельные варианты гена CYP19 (ароматазы р450) и активность ароматазы р450 у больных синдромом поликистозных яичников. Медицинская генетика. 2012; 4: 36-41.
  7. Badawy A., Elnashar A. Treatment options for polycystic ovary syndrome. Int. J. Womens Health. 2011; 3: 25-35.
  8. Deb S., Campbell B. K., Pincott-Allen C. et al. Quantifying effect of combined oral contraceptive pill on functional ovarian reserve as measured by serum anti-Müllerian hormone and small antral follicle count using three-dimensional ultrasound. Ultrasound. Obstet. Gynecol. 2012; 39 (5): 574-80.
  9. Poli F., Dreno B., Verschoore M. An epidemiological study of acne in female adults: results of a survey conducted in France. J. Eur. Acad. Dermatol. Venereol. 2001;15 (6): 541-5.
  10. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr. Rev. 1997; 18: 774-800.
  11. Ehrmann D. A., Cavaghan M. K., Imperial J. et al. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 1997; 82 (2): 524-30.
  12. Fitzpatrick S. L., Richards J. S. Regulation of cytochrome P450 aromatase messenger ribonucleic acid and activity by steroids and gonadotropins in rat granulosa cells. Endocrinology. 1991; 129 (3): 1452-62.
  13. Grossman M., Nakajima S., Fallat M., Siow Y. Müllerian inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture. Fertil. Steril. 2008; 89: 1364-70.
  14. Santen R. et al. History of aromatase: saga of an important biological mediator and therapeutic target. J. Endocr. Rev. 2009; 30 (4): 343-75.
  15. Ji Hee Yoo, Hye Ok Kim, Sun Wha Cha et al. Age specific serum anti-Müllerian hormone levels in 1,298 Korean women with regular menstruation. Clin. Exp. Reprod. Med. 2011; 38 (2): 93-7.
  16. Jones M. E., Boon W. C., McInnes K. et al. Recognizing rare disorders: aromatase deficiency. Nat. Clin. Pract. Endocrinol. Metab. 2007; 3: 414-21.
  17. Laven J. S. E., Mulders A. M., Visser J. et al. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J. Clin. Endocrinol. Metabolism. 2004; 89: 318-23.
  18. Lobo R. A., Carmina E. The importance of diagnosing the polycystic ovary syndrome. Annals of Internal medicine. 2000; 132 (12): 989-93.
  19. Morisihima A., Grumbach M. M., Simpson E. R. et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J. Clin. Endocrinol. Metab. 1995; 80: 3689-98.
  20. Nilsson E. E., Schindler R., Savenkova M. I., Skinner M. K. Inhibitory actions of anti-Müllerian hormone (AMH) on ovarian primordial follicle assembly. PLoS One. 2011; 6 (5): 20087.
  21. Pellatt L., Rice S., Mason H. D. Anti-Müllerian hormone and polycystic ovary syndrome: a mountain too high? Reproduction. 2010; 139 (5): 825-33.
  22. Rotterdam E. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 2004; 81 (1): 19-25.
  23. Stewart P. M., Krozowski Z. S. 11 beta-hydroxysteroid dehydrogenase. Vitam. Horm. 1999; 57: 249-324.
  24. Van Rooij I. A., Broekmans F. J., te Velde E. R. et al. Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum. Reprod. 2002; 17: 3065-71.

Copyright (c) 2014 Nikolayenkov I.P., Potin V.V., Tarasova M.A., Tkachenko N.N., Yarmolinskaya M.I., Timofeyeva Y.M., Samoylovich Y.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies